Moleculin Biotech CS (MBRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2019 | 09-2019 | 06-2019 | 03-2019 | 12-2018 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 10,735 | 15,409 | 18,695 | 8,782 | 7,134 |
| TOTAL | $13,484 | $18,586 | $20,202 | $9,613 | $7,974 |
| Non-Current Assets | |||||
| PPE Net | 316 | 358 | 401 | 431 | 463 |
| Intangibles | 11,148 | 11,148 | 11,148 | 11,148 | 11,148 |
| Other Non-Current Assets | 287 | 306 | 103 | 106 | 0 |
| TOTAL | $11,751 | $11,812 | $11,652 | $11,685 | $11,611 |
| Total Assets | $25,235 | $30,398 | $31,854 | $21,298 | $19,585 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 3,570 | 4,299 | 2,647 | 4,050 | 3,698 |
| Other current liabilities | N/A | 6,820 | 6,944 | 2,386 | 180 |
| TOTAL | $3,570 | $11,119 | $9,591 | $6,436 | $3,878 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 6,094 | 304 | 171 | 180 | 1,328 |
| TOTAL | $6,094 | $304 | $171 | $180 | $1,435 |
| Total Liabilities | $9,664 | $11,423 | $9,762 | $6,616 | $5,313 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 24 | 20 | 20 | 20 | 13 |
| Common Shares | 46 | 46 | 45 | 34 | 29 |
| Retained earnings | -39,561 | -35,763 | -31,618 | -30,397 | -26,356 |
| Other shareholders' equity | 31 | 19 | 22 | 24 | 35 |
| TOTAL | $15,571 | $18,975 | $22,092 | $14,682 | $14,272 |
| Total Liabilities And Equity | $25,235 | $30,398 | $31,854 | $21,298 | $19,585 |